Solstice Neurosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.solsticeneuro.com
Clinical Trials
2
Active:0
Completed:2
Trial Phases
2 Phases
Phase 2:1
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 4
1 (50.0%)An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia
Phase 4
Completed
- Conditions
- Cervical Dystonia
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Solstice Neurosciences
- Target Recruit Count
- 502
- Registration Number
- NCT00702754
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- Drooling
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Solstice Neurosciences
- Target Recruit Count
- 54
- Registration Number
- NCT00515437
- Locations
- 🇺🇸
Dr Virgilio Evidente, Scottsdale, Arizona, United States
🇺🇸Dr. Ronald Ziman, Northridge, California, United States
🇺🇸Dr. James Sutton, Oxnard, California, United States
News
No news found